Proteus Digital Health, Inc

Prnewswire | August 25, 2020

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased in urine drug tests, climbing to the highest level since 2003 (4.5%) and more than 28% percent higher than the thirty-year low of 3.5 percent recorded between 2010 and 2012. In addition to overall increases in workforce drug ...

bccourier | April 16, 2020

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Business Insights

Symbio Generrics | November 25, 2022

Symbio Generrics India Private Limited a specialized Active Pharmaceutical Ingredients & Intermediates manufacturing and marketing organization, announced that it has completed an equity capital raise from Ascent Capital, a leading growth-capital focused private equity fund. Symbio was founded by pharmaceutical professionals, Salim Shaikh and Abhijit Kale. They were soon joined by the third promoter, Akash Puranik; all of whom possess decades of experience in the global pharma...

Pharma Tech

Emerald Health Pharmaceuticals | October 14, 2022

Emerald Health Pharmaceuticals Inc. a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis and multiple sclerosis. Titled &...